Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

Core Insights - Novartis will present over 20 abstracts from its immunology portfolio at the American Academy of Dermatology (AAD) Annual Meeting, showcasing advancements in treatments for chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) [1][2][3] Immunology Portfolio Highlights - New data on Rhapsido (remibrutinib) will be presented, focusing on early symptom improvement in CSU patients, with significant changes in daily itch and hives severity scores observed as early as week 1 [2][4] - Long-term efficacy data for Cosentyx (secukinumab) will be shared, reinforcing its continuous use in HS and psoriasis, including a matched adjusted indirect comparison of its safety and flare prevention against bimekizumab [4][5] Key Abstracts - Notable abstracts include: - "Early symptom improvement with remibrutinib in chronic spontaneous urticaria" (Abstract 71668) [3] - "Flare prevention and safety of secukinumab vs bimekizumab in hidradenitis suppurativa" (Abstract 76852) [5] - "Effectiveness of Secukinumab in Preventing Psoriatic Arthritis in Patients with Moderate to Severe Psoriasis" (Abstract 73859) [5] Commitment to Innovation - Novartis emphasizes its dedication to advancing science in immunology, aiming to provide relief for patients with autoimmune diseases through a robust pipeline and innovative treatments [6]